-
1
Allo-HSCT is a curative treatment for hematologic malignancies and certain non-malignant conditions, despite potential life-threatening complications.
-
2
Common complications post-allo-HSCT include graft versus host disease, disease recurrence, conditioning toxicity, and severe infections.
-
3
Personalized conditioning strategies, such as ruxolitinib and decitabine with mBu/Cy, show promise in high-risk AML/MDS patients.
-
4
Graft versus host disease remains a major complication, with steroid-refractory cases requiring alternative treatments like cyclophosphamide and extracorporeal photopheresis.
-
5
Thrombotic microangiopathy and early platelet transfusion refractoriness are additional complications, with novel treatments being explored for refractory cases.
